AMPK activation: a therapeutic target for type 2 diabetes?

被引:367
|
作者
Coughlan, Kimberly A. [1 ]
Valentine, Rudy J. [1 ]
Ruderman, Neil B. [1 ]
Saha, Asish K. [1 ]
机构
[1] Boston Univ, Med Ctr, Dept Med, Endocrinol & Diabet, Boston, MA USA
来源
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY | 2014年 / 7卷
关键词
adenosine monophosphate-activated protein kinase; type; 2; diabetes; insulin resistance; drug therapy;
D O I
10.2147/DMSO.S43731
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, a-cell dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have T2D, and the International Diabetes Federation projects that this number will increase to nearly 600 million by 2035. There is a great need for more effective treatments for maintaining glucose homeostasis and improving insulin sensitivity. AMP-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase whose activation elicits insulin-sensitizing effects, making it an ideal therapeutic target for T2D. AMPK is an energy-sensing enzyme that is activated when cellular energy levels are low, and it signals to stimulate glucose uptake in skeletal muscles, fatty acid oxidation in adipose (and other) tissues, and reduces hepatic glucose production. There is substantial evidence suggesting that AMPK is dysregulated in animals and humans with metabolic syndrome or T2D, and that AMPK activation (physiological or pharmacological) can improve insulin sensitivity and metabolic health.-Numerous pharmacological agents, natural compounds, and hormones are known to activate AMPK, either directly or indirectly-some of which (for example, metformin and thiazolidinediones) are currently used to treat T2D. This paper will review the regulation of the AMPK pathway and its role in T2D, some of the known AMPK activators and their mechanisms of action, and the potential for future improvements in targeting AMPK for the treatment of T2D.
引用
收藏
页码:241 / 253
页数:13
相关论文
共 50 条
  • [41] NEW THERAPEUTIC APPROACHES IN TYPE 2 DIABETES
    Scheen, A. J.
    ACTA CLINICA BELGICA, 2008, 63 (06) : 402 - 407
  • [42] Mitochondrial Dysfunction and Mitophagy in Type 2 Diabetes: Pathophysiology and Therapeutic Targets
    Apostolova, Nadezda
    Vezza, Teresa
    Muntane, Jordi
    Rocha, Milagros
    Victor, Victor M.
    ANTIOXIDANTS & REDOX SIGNALING, 2023, 39 (4-6) : 278 - 320
  • [43] Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
    Hallakou-Bozec, Sophie
    Vial, Guillaume
    Kergoat, Micheline
    Fouqueray, Pascale
    Bolze, Sebastien
    Borel, Anne-Laure
    Fontaine, Eric
    Moller, David E.
    DIABETES OBESITY & METABOLISM, 2021, 23 (03) : 664 - 673
  • [44] Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
    Kabir, Md Tanvir
    Mitu, Jannatul Ferdous
    Akter, Raushanara
    Akhtar, Muhammad Furqan
    Saleem, Ammara
    Al-Harrasi, Ahmed
    Bhatia, Saurabh
    Rahman, Md Sohanur
    Damiri, Fouad
    Berrada, Mohammed
    Rahman, Md Habibur
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (31) : 46385 - 46404
  • [45] Remote ischemic conditioning: A potential therapeutic strategy of type 2 diabetes
    Liu, Jie
    Sun, Xin
    Jin, Hang
    Yan, Xiu-Li
    Huang, Shuo
    Guo, Zhen-Ni
    Yang, Yi
    MEDICAL HYPOTHESES, 2021, 146
  • [46] Sleep-Time Blood Pressure as a Therapeutic Target for Cardiovascular Risk Reduction in Type 2 Diabetes
    Hermida, Ramon C.
    Ayala, Diana E.
    Mojon, Artemio
    Fernandez, Jose R.
    AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (03) : 325 - 334
  • [47] Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes
    Mandosi, Elisabetta
    Giannetta, Elisa
    Filardi, Tiziana
    Lococo, Manuela
    Bertolini, Camilla
    Fallarino, Mara
    Gianfrilli, Daniele
    Venneri, Mary Anna
    Lenti, Luisa
    Lenzi, Andrea
    Morano, Susanna
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (12) : 1617 - 1622
  • [48] Therapeutic perspectives for type 2 diabetes mellitus: Molecular and clinical insights
    Mauvais-Jarvis, F
    Andreelli, F
    Hanaire-Broutin, H
    Charbonnel, B
    Girard, J
    DIABETES & METABOLISM, 2001, 27 (04) : 415 - 423
  • [49] Plin5: A potential therapeutic target for type 2 diabetes mellitus
    Wei, Mengjuan
    Wang, Yan
    Zhang, Yufei
    Qiao, Yun
    DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01)
  • [50] The Role of the Kidney in Hyperglycemia A New Therapeutic Target in Type 2 Diabetes Mellitus
    Hinnen, Debbie
    JOURNAL OF CARDIOVASCULAR NURSING, 2013, 28 (02) : 157 - 165